KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Deferred Revenue (2019 - 2026)

Esperion Therapeutics filings provide 7 years of Current Deferred Revenue readings, the most recent being $34.5 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 304.75% to $34.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $34.5 million, a 304.75% increase, with the full-year FY2025 number at $34.5 million, up 304.75% from a year prior.
  • Current Deferred Revenue hit $34.5 million in Q4 2025 for Esperion Therapeutics, up from $30.7 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $34.5 million in Q4 2025 to a low of $2.5 million in Q1 2021.
  • Median Current Deferred Revenue over the past 5 years was $10.3 million (2023), compared with a mean of $13.5 million.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 624.32% in 2023 and later crashed 84.52% in 2025.
  • Esperion Therapeutics' Current Deferred Revenue stood at $5.7 million in 2021, then tumbled by 38.29% to $3.5 million in 2022, then skyrocketed by 624.32% to $25.4 million in 2023, then crashed by 66.47% to $8.5 million in 2024, then skyrocketed by 304.75% to $34.5 million in 2025.
  • The last three reported values for Current Deferred Revenue were $34.5 million (Q4 2025), $30.7 million (Q3 2025), and $22.3 million (Q2 2025) per Business Quant data.